| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b5f41889212134f724ee94357d02f4b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-35 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 |
| filingDate |
2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7780b5e36ba88ab85cbf5f209f76d84e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_971c786af9de168358e253a1a6a8ab7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4b61c353e4f35d95b10107757b1cf57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c312d61c5e69a7c26a6a88b29c5de7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2de5c61011552a06efa917b081803733
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04fb48c23969bba7ee7236724489c62e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8f2645ec7244af773da0588a2fe3651
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d91444f23408fb0c0fe816f662d07e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4490b90b7a0c98e890871a37dc16b68e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_715166983bae0cd20e7bc7c11e9b06e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b3641df2725a93b0039d318375d4738
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_326f7722a07e93ec8931dc6419d70fdb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1545bf26cbaf782f87e70ee9ffbdab3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_093cb9d8f3755e55f7acd9d745bc487d |
| publicationDate |
2020-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200098831-A |
| titleOfInvention |
Novel site-specific antibody fragment platform |
| abstract |
The present invention relates to a Fab fragment that specifically binds to HER2 (human epidermal growth factor receptor 2), comprising: (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 5 (V H ); (b) heavy chain constant region 1 (C H1 ) comprising the amino acid sequence of SEQ ID NO: 6; (c) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11 (V L ); And (d) a site-specific light chain constant region (sC L ) comprising the amino acid sequence of SEQ ID NO: 15. The novel site-specific antibody fragmentation platform of the present invention provides mass production and homogenization of site-specific mono-valent or di-valent Fab fragments that can replace existing antibody drugs through E. coli. It can be prepared, and the binding affinity for HER2 is similar or superior to Herceptin (trastuzumab), so it can be usefully used as a technology for producing antibody-drug conjugates in the fields of medicine and pharmaceuticals. |
| priorityDate |
2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |